News: Translational Research and Interventional Oncology Research Program
A recent study shows that a cell receptor, SSTR2, is a candidate biomarker for poor prognosis and a potential therapeutic target for small cell lung cancer.
Patient Joe Lofaro credits the teamwork of Nishitha Reddy, MBBS, MSCI, and other clinicians at VUMC for diagnosing him with the rare blood cancer Erdheim-Chester disease.
Cardiovascular complications linked to immune checkpoint inhibitors include myocarditis, pericarditis, vasculitis and arrhythmias and occur early in the course of treatment, Vanderbilt researchers report.
Jeremy Warner, MD, is the 2018 recipient of the New Investigator Award from the American Medical Informatics Association (AMIA).
Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.
Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Vanderbilt investigators have conducted a prospective multicenter study on how extracorporeal photopheresis works in treating chronic graft-versus-host disease (cGVHD) — a complication of bone marrow or stem cell transplant that occurs when donor cells attack the recipient.
A recent study suggests that a transporter protein called xCT may be potential therapeutic target in lung cancer.
Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.